Schwartz Daniel Mark 4
4 · RxSight, Inc. · Filed Aug 5, 2021
Insider Transaction Report
Form 4
RxSight, Inc.RXST
Schwartz Daniel Mark
Director
Transactions
- Conversion
Series C Preferred Stock
2021-08-03−3,872→ 0 total→ Common Stock (3,969 underlying) - Conversion
Common Stock
2021-08-03+3,969→ 407,647 total
Footnotes (2)
- [F1]All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
- [F2]The number of shares reported as beneficially held by the Reporting Person in the Form 3 filed July 29, 2021 incorrectly overstated the number of shares held by 11,012 shares. The correct number of shares should have been reported as 403,678.